Ana Carolina Covre Coan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Carolina Covre Coan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alonzo Armani Prata
Federal University of Espírito Santo Vitória Brazil
2 shared publications - André Milani Reis
State University of Campinas School of Medicine, Campinas, Brazil
2 shared publications - Elísio Bulhões
College of Higher Education of the United Amazon, Redenção, Para, Brazil
2 shared publications - Matheus Vanzin Fernandes
Federal University of Health Sciences of Porto Alegre Porto Alegre Brazil
2 shared publications - Natália Junkes Milioli
Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil
2 shared publications - Otavio Cosendey Martins
Department of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil
2 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (10)
Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials
- 28 August 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (10)
Olezarsen for the treatment of hypertriglyceridemia: A Bayesian reanalysis of randomized controlled trials
- Open Access
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (3) , 308-309
Reply to the Letter to the Editor: “Albumin in hepatic encephalopathy: Evidence, prioritization, and the affordability gap in decompensated cirrhosis”
Hepatology Forum (HF) is the double-blind peer-reviewed, open access, international official journal of Turkish Association for the Study of the Liver (TASL). Yearly four issues of the journal are being published (January, April, July, October). The journal’s publication language is English.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (3) , 308-309
Open AccessReply to the Letter to the Editor: “Albumin in hepatic encephalopathy: Evidence, prioritization, and the affordability gap in decompensated cirrhosis”
Hepatology Forum (HF) is the double-blind peer-reviewed, open access, international official journal of Turkish Association for the Study of the Liver (TASL). Yearly four issues of the journal are being published (January, April, July, October). The journal’s publication language is English.
- Open Access
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 4-13
Use of albumin in patients with hepatic encephalopathy: A systematic review and meta-analysis of randomized controlled studies with trial sequential analysis
Background and Aim: Hepatic encephalopathy (HE) is a complication of cirrhosis and one of the most important manifestations of this disease. Intravenous albumin may have the potential to mitigate oxidative stress injury inherent to the pathogenesis of HE. Our study aims to evaluate the efficacy and safety of albumin for the treatment of HE. Materials and Methods: We performed a systematic review and meta-analysis using the PubMed, Embase, and Cochrane databases. We searched for randomized controlled trials (RCTs) comparing albumin to placebo in patients with HE and decompensated cirrhosis. The outcomes were mortality and clinical improvement of HE. The odds ratio (OR) was used for binary outcomes and the mean difference (MD) for continuous outcomes with their respective 95% confidence interval (CI). Heterogeneity was assessed using the Cochran Q test and I² statistics. Trial sequential analysis (TSA) was performed for all outcomes. Results: This study included four RCTs, amounting to 306 patients. There was a significant difference favoring albumin use for mortality (OR 0.44; 95% CI 0.24 to 0.79; p=0.007; I2=0%) and for HE improvement (OR 2.41; 95% CI 1.22 to 4.75, p=0.011; I2=34.9%) compared to placebo. There was no significant difference in ammonia levels (p=0.580), liver transplantation (p=0.732), and significant adverse events (AE) rate (p=0.586). TSA revealed that the pooled effect is statistically significant for mortality reduction with albumin use; however, regarding sample size, the result is not definitive. Conclusion: In patients with HE, intravenous albumin leads to HE improvement and reduced mortality, without an increase in AE rates. However, the TSA indicated that further studies are required to draw precise evidence regarding the use of albumin to reduce mortality in this population.
- 1 January 2026
- Published by Kare Publishing in Hepatology Forum
- Vol. 7 (1) , 4-13
Open AccessUse of albumin in patients with hepatic encephalopathy: A systematic review and meta-analysis of randomized controlled studies with trial sequential analysis
Background and Aim: Hepatic encephalopathy (HE) is a complication of cirrhosis and one of the most important manifestations of this disease. Intravenous albumin may have the potential to mitigate oxidative stress injury inherent to the pathogenesis of HE. Our study aims to evaluate the efficacy and safety of albumin for the treatment of HE. Materials and Methods: We performed a systematic review and meta-analysis using the PubMed, Embase, and Cochrane databases. We searched for randomized controlled trials (RCTs) comparing albumin to placebo in patients with HE and decompensated cirrhosis. The outcomes were mortality and clinical improvement of HE. The odds ratio (OR) was used for binary outcomes and the mean difference (MD) for continuous outcomes with their respective 95% confidence interval (CI). Heterogeneity was assessed using the Cochran Q test and I² statistics. Trial sequential analysis (TSA) was performed for all outcomes. Results: This study included four RCTs, amounting to 306 patients. There was a significant difference favoring albumin use for mortality (OR 0.44; 95% CI 0.24 to 0.79; p=0.007; I2=0%) and for HE improvement (OR 2.41; 95% CI 1.22 to 4.75, p=0.011; I2=34.9%) compared to placebo. There was no significant difference in ammonia levels (p=0.580), liver transplantation (p=0.732), and significant adverse events (AE) rate (p=0.586). TSA revealed that the pooled effect is statistically significant for mortality reduction with albumin use; however, regarding sample size, the result is not definitive. Conclusion: In patients with HE, intravenous albumin leads to HE improvement and reduced mortality, without an increase in AE rates. However, the TSA indicated that further studies are required to draw precise evidence regarding the use of albumin to reduce mortality in this population.